Moderna-Merck’s $12 Billion Cancer Vaccine: Reality or Fiction?: BI Replay

On Demand

Duration: 59 Minutes

Original Date: August 27, 2026

First name

Last name

Business email

Business phone

Company

Job role

Industry

City

Country or Region

State or Province Optional

Yes, I would like to be contacted by a representative to learn more about Bloomberg's solutions and services.

What are you interested in learning more about?

By submitting this information, I agree to the privacy policy and to learn more about products and services from Bloomberg.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

This webinar will dive into each of the potential indications for Moderna-Merck’s cancer vaccine using Bloomberg Intelligence’s proprietary and interactive cancer models to assess the market dynamics in each disease and estimate a peak and risk adjusted sales potential for each indication. Please join Sam Fazeli, Director of Research and Senior Pharmaceuticals Analyst; Biotech Analysts Max Nisen and Javier Manso; and Cancer Disease Specialists An Li, Eda Erdogmus and Anna Wernick

Moderna-Merck’s $12 Billion Cancer Vaccine: Reality or Fiction?: BI Replay

Access a broad range of analysis, research, insight and actionable ideas with Bloomberg webinars.